파킨슨병 치료제 시장 : 약제 클래스별, 치료법별, 투여 경로별, 대상 영역별, 유통 채널별, 최종 사용자별 시장 예측(2026-2032년)

The Parkinson's Disease Therapeutics Market is projected to grow by USD 8.98 billion at a CAGR of 6.50% by 2032.

Parkinson's disease therapeutics address a progressive neurodegenerative disorder marked by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability, as well as non-motor complications including sleep disruption, depression, autonomic dysfunction, constipation, pain, fatigue, and cognitive impairment.

The World Health Organization reports that global Parkinson's disease prevalence exceeded 8.5 million people in 2019 and has more than doubled over the past 25 years. This creates sustained clinical demand for levodopa-based regimens, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, device-aided therapies, rehabilitative care, and investigational disease-modifying approaches targeting underlying neurodegeneration.

Transformative Shifts in the Therapeutics Landscape

The Parkinson's disease therapeutics landscape is shifting from symptom control alone toward earlier diagnosis, personalized treatment sequencing, and longer-lasting delivery systems. Clinicians increasingly combine pharmacologic therapy with deep brain stimulation, infusion-based approaches, rehabilitation, speech and physical therapy, and digital monitoring to manage fluctuating disease burden and preserve daily function.

Pipeline activity is also moving toward alpha-synuclein biology, neuroinflammation, mitochondrial dysfunction, lysosomal pathways, gene therapy, cell therapy, and biomarker-guided trials. However, payers and health systems continue to require evidence of meaningful improvement in daily function, safety, adherence, caregiver burden, and total cost of care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across Parkinson's disease drug discovery, clinical development, diagnosis, and care delivery. AI-enabled analytics can support target identification, molecule screening, patient stratification, imaging interpretation, speech analysis, gait assessment, tremor characterization, medication response tracking, and remote monitoring through wearable and smartphone-based data.

The strongest near-term impact is expected in trial enrichment and digital endpoints, where objective movement, sleep, speech, and activity data may reduce variability and improve sensitivity to treatment effects. Adoption still depends on clinical validation, explainable models, cybersecurity, representative datasets, physician workflow integration, and alignment with medical device and software regulatory requirements.

Key Regional Insights

North America remains a leading environment for Parkinson's disease therapeutics due to advanced neurology infrastructure, FDA-regulated innovation pathways, high diagnosis rates, clinical trial activity, and strong adoption of specialty drugs and device-aided care. Europe benefits from established movement disorder networks, EMA oversight, national reimbursement systems, health technology assessment, and active research in pharmacologic, surgical, digital, and rehabilitative Parkinson's disease care.

Asia-Pacific is gaining strategic importance as aging populations in Japan, China, South Korea, India, and Australia expand treatment demand and accelerate the need for neurologist access, essential medicines, and advanced therapies. Latin America, led by Brazil and Mexico, shows improving access through public health systems and expanding private care, although reimbursement and specialist availability remain uneven. The Middle East, especially GCC health systems, is investing in specialty hospitals, imported innovative medicines, and neurology centers, while Africa remains constrained by underdiagnosis, limited neurologist density, fragmented access to dopaminergic therapy, and affordability barriers.

Key Group Insights

The European Union and G7 anchor much of the global Parkinson's disease therapeutics innovation ecosystem through regulated clinical trials, academic neurology centers, pharmacovigilance systems, health technology assessment, and reimbursement for therapies with proven clinical value. NATO member countries also contribute through resilient medical supply chains, cross-border research collaboration, preparedness-focused health infrastructure, and standardized quality expectations across many advanced healthcare systems.

BRICS countries represent scale, manufacturing capacity, and expanding access to generics and affordable neurologic care, especially in China, India, and Brazil, while Russia emphasizes localized supply resilience. ASEAN markets are shaped by rising diagnosis, public hospital access, variable reimbursement, and growing demand for cost-effective Parkinson's disease medicines. GCC countries support premium specialty care, imported branded medicines, digital health adoption, and investment in neurology centers of excellence, strengthening access to advanced treatment pathways for eligible patients.

Key Country Insights

The United States leads commercial adoption through FDA approvals, specialist networks, Medicare coverage, movement disorder centers, and active clinical trials, while Canada emphasizes public reimbursement, guideline-based care, and equitable access across provinces. Mexico and Brazil show growing demand for affordable generics, expanded neurologic care, and improved continuity of treatment, with Brazil's public health system playing a central access role for essential medicines and specialist services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on health technology assessment, national reimbursement decisions, neurologist-led care pathways, and established use of levodopa and adjunctive therapies, while Russia focuses on localized supply resilience and access continuity. China is expanding access through hospital reform, reimbursement listing, domestic manufacturing, and broader neurology capacity; India is driven by high patient volume, generic availability, affordability considerations, and expanding specialist services in urban centers. Japan is shaped by super-aged demographics, high clinical awareness, and advanced management of motor complications, while Australia and South Korea combine strong reimbursement frameworks, modern neurology practice, and adoption of selected device-aided and digital care approaches.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that address motor fluctuations, dyskinesia, wearing-off, non-motor symptoms, adherence, safety, and caregiver burden. Strong differentiation requires real-world evidence, patient-reported outcomes, objective digital measures, and measurable functional benefit beyond traditional rating scales.

Organizations should pair pipeline investment with AI-enabled trial design, decentralized monitoring, biomarker strategies, and inclusive enrollment to reflect age, sex, ethnicity, disease stage, and comorbidity diversity. Market access teams need country-specific pricing, evidence, reimbursement, and affordability plans, while manufacturers should strengthen supply reliability for levodopa and other essential Parkinson's disease medicines to reduce treatment interruptions.

Research Methodology

This executive summary is based on triangulated secondary research from publicly available clinical, regulatory, epidemiologic, and health policy sources, including WHO disease burden data, national regulatory frameworks, treatment guidelines, peer-reviewed literature, clinical trial registries, pharmacovigilance references, and reimbursement information.

The analysis evaluates therapy classes, pipeline direction, regional access patterns, artificial intelligence adoption, digital health integration, technology use, and market access dynamics. Insights are validated through consistency checks across authoritative sources and interpreted using a structured healthcare market assessment framework focused on clinical relevance, regulatory context, access conditions, and evidence quality.

Conclusion

Parkinson's disease therapeutics will remain a high-priority healthcare category as prevalence rises with population aging and as patient needs expand beyond symptomatic motor control to include non-motor symptoms, long-term function, independence, and caregiver support. Current standards of care remain essential, but the competitive landscape is increasingly defined by delivery innovation, biomarkers, digital endpoints, and evidence-backed disease-modifying research.

Organizations that combine clinical differentiation, AI-enabled development, robust safety evidence, reliable supply, and region-specific access strategies will be best positioned to improve outcomes and create durable value in Parkinson's disease care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Parkinson's Disease Therapeutics Market, by Drug Class

• 7.1. Anticholinergics
  • 7.1.1. Benztropine
  • 7.1.2. Trihexyphenidyl
• 7.2. COMT Inhibitors
  • 7.2.1. Entacapone
  • 7.2.2. Tolcapone
• 7.3. Dopamine Agonists
• 7.4. Levodopa
• 7.5. MAO-B Inhibitors

8. Parkinson's Disease Therapeutics Market, by Therapy Type

• 8.1. Medications
• 8.2. Non-Pharmacological Therapies
  • 8.2.1. Deep Brain Stimulation
  • 8.2.2. Physiotherapy
  • 8.2.3. Speech & Language Therapy

9. Parkinson's Disease Therapeutics Market, by Route Of Administration

• 9.1. Infusion
• 9.2. Injectable
• 9.3. Oral
• 9.4. Transdermal

10. Parkinson's Disease Therapeutics Market, by Targeted Area

• 10.1. Atypical Parkinsonian
• 10.2. Drug-Induced Parkinsonism
• 10.3. Genetic Parkinson's
• 10.4. Idiopathic Parkinson's
• 10.5. Vascular Parkinsonism

11. Parkinson's Disease Therapeutics Market, by Distribution Channel

• 11.1. Offline
  • 11.1.1. Hospital Pharmacy
  • 11.1.2. Retail Pharmacy
• 11.2. Online

12. Parkinson's Disease Therapeutics Market, by End User

• 12.1. Clinics
• 12.2. Home Care
• 12.3. Hospitals

13. Parkinson's Disease Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Parkinson's Disease Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Parkinson's Disease Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AbbVie Inc.
• 17.2. Acadia Pharmaceuticals Inc.
• 17.3. Novartis AG
• 17.4. UCB S.A.
• 17.5. Amneal Pharmaceuticals LLC
• 17.6. Otsuka Pharmaceutical Co., Ltd.
• 17.7. Sumitomo Pharma Co., Ltd.
• 17.8. Orion Corporation
• 17.9. Teva Pharmaceutical Industries Limited
• 17.10. H. Lundbeck A/S
• 17.11. Eisai Co., Ltd.
• 17.12. Amyl Therapeutics SRL
• 17.13. Apotex Inc.
• 17.14. Aspen Neuroscience, Inc.
• 17.15. Bayer AG
• 17.16. Biogen Inc.
• 17.17. BlueRock Therapeutics LP by Bayer AG
• 17.18. Brainstorm Cell Therapeutics Ltd.
• 17.19. Bristol-Myers Squibb Company
• 17.20. Cerevance, LLC
• 17.21. Cipla Limited
• 17.22. Denali Therapeutics Inc.
• 17.23. Eli Lilly and Company
• 17.24. F. Hoffmann-La Roche Ltd.
• 17.25. GlaxoSmithKline plc
• 17.26. Lupin Limited
• 17.27. Merck & Co., Inc.
• 17.28. Muna Therapeutics ApS
• 17.29. Pfizer Inc.
• 17.30. Torrent Pharmaceuticals Ltd.
• 17.31. Zydus Lifesciences Limited